Search...
Roth MKM Remains a Buy on PolyPid (PYPD)
I'm PortAI, I can summarize articles.
Roth MKM's Boobalan Pachaiyappan maintains a Buy rating on PolyPid with a $9.00 price target. Despite Pachaiyappan's average return of -10.0% and a 34.31% success rate, the general analyst consensus is a Strong Buy for PolyPid, with an average price target of $11.00.
In a report released today, Boobalan Pachaiyappan from Roth MKM maintained a Buy rating on PolyPid, with a price target of $9.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Pachaiyappan is an analyst with an average return of -10.0% and a 34.31% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Cingulate Inc, CervoMed, and PolyPid.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for PolyPid with a $11.00 average price target.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments